En español
NIDA

ARP Research and Funding Priorities

Funding Priorities:

Research Priorities:

Domestic:

  • Reducing racial/ethnic disparities in HIV testing, access, and utilization of treatment and services both to improve individual health and to reduce new HIV infections
  • Eliminating disparities in the continuum of care for drug users, youth, and racial, ethnic, and sexual minorities
  • Seek, test, treat, and retain—expanding outreach, HIV testing, linkage, and retention in care for hard-to-reach populations
  • Drug abuse treatment as HIV prevention
  • Understanding transmission of HIV among drug users (both injection and non-injection) and their networks
  • Interventions to reduce HIV acquisition and transmission among drug users, including those involved in the criminal justice system
  • Research on substance abuse, risky decision-making, impulsivity, and HIV transmission among adolescents and adults
  • Research on coordinating and improving treatment and services for HIV, drug abuse, and co-occurring infections such as HCV
  • Prevention and treatment of HCV/HIV coinfection among drug users
  • Studies to enhance adherence to treatment for HIV and comorbid conditions, including use of technology-based interventions
  • Research to improve long term retention in HIV care for drug using populations
  • Studies of comorbid conditions that disproportionately affect HIV+ drug users such as neurocognitive impairment, accelerated aging, and cardiovascular disease
  • Drug abuse, HIV, and the brain
  • Research on CNS HIV persistence and strategies for eradication
  • Basic research on HIV and drug abuse, including genetics, epigenetics, proteomics, and systems biology studies
  • Training new AIDS researchers

International:

  • Develop prevention strategies addressing non-injection drug use such as stimulants (e.g. methamphetamine, cocaine, crack) in vulnerable populations (e.g., MSM, young women) where prevalence is high (e.g., Latin America, Asia, Africa)
  • Develop prevention strategies addressing HIV/injection drug use epidemics in different geographic areas (Russia, China, SE Asia, India, Central Asia, Eastern/Central Europe)
  • Develop new methods for gathering HIV epidemiological data and tracking HIV diffusion and changes in populations affected by HIV
  • Assess role(s) of immigration and migration on HIV transmission
  • Drug abuse treatment as HIV prevention, including research on long-acting, sustainable therapies
  • HIV/AIDS treatment as HIV prevention adapted to local conditions
  • Implementation science research to guide scale-up of cost-effective interventions
  • HIV and co-infections (e.g., HCV, TB)
  • Training new AIDS researchers

This page was last updated October 2014

Get this Publication

    Link to aids.gov